文献速递血脂与心血管预防

载脂蛋白B与非高密度脂蛋白胆固醇及甘油三酯的不一致性:心血管预防的意义

Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
PubMed 文献 · Eur Heart J · 2024-01-01

在293 876名无心血管疾病的英国生物银行成人中,中位随访11年,发现相同LDL-C、非HDL-C或甘油三酯水平下apoB分布范围宽,且高apoB与低apoB的10年ASCVD事件率差异显著。调整标准风险因素后,apoB残差仍显著预测新发ASCVD,而LDL-C、非HDL-C或甘油三酯残差在包含apoB的模型中不显著,表明这些指标不能充分替代apoB。

要点

  • 相同LDL-C、非HDL-C或甘油三酯水平下apoB变异大,10年ASCVD事件率差异有临床意义。
  • 调整LDL-C、非HDL-C或甘油三酯及HDL-C后,apoB残差仍显著预测ASCVD。
  • LDL-C、非HDL-C和甘油三酯不是apoB的充分替代指标,临床应重视apoB检测。

核心结论

  • LDL-C、非HDL-C和甘油三酯在临床 care 中不是apoB的 adequate proxies,apoB应作为风险评估的关键指标。

研究设计与样本

  • 基于英国生物银行293 876名40-73岁无心血管疾病成人的前瞻性队列分析,中位随访11年。

主要发现

  • apoB与LDL-C和非HDL-C高度相关(Pearson r=.96,P<.001),与对数甘油三酯相关性较低(r=.42,P<.001)。
  • 在LDL-C 130 mg/dL时,捕获95%观测值的apoB范围为85.8-108.8 mg/dL;非HDL-C 160 mg/dL时为88.3-112.4 mg/dL;甘油三酯115 mg/dL时为67.8-147.4 mg/dL。
  • 在上述水平±10 mg/dL内,apoB高于均值+1SD vs 低于均值-1SD的10年ASCVD率:LDL-C组7.3 vs 4.0,非HDL-C组6.4 vs 4.6,甘油三酯组7.0 vs 4.6(均P<.001)。
  • 随访期间19 982例新发ASCVD事件,调整LDL-C和HDL-C后apoB残差HR 1.06(95%CI 1.0-1.07),调整非HDL-C和HDL-C后HR 1.04(95%CI 1.03-1.06),调整甘油三酯和HDL-C后HR 1.13(95%CI 1.12-1.15)。
  • 包含apoB的模型中,LDL-C、非HDL-C或对数甘油三酯的残差均不显著。

临床怎么用

  • 临床评估ASCVD风险时,应优先检测apoB而非仅依赖LDL-C、非HDL-C或甘油三酯。
  • 对于LDL-C、非HDL-C或甘油三酯达标但apoB升高的患者,需强化风险管理。

局限性

  • 研究基于英国生物银行队列,结果外推需谨慎。
  • 观察性设计,不能完全排除残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Despite growing evidence that apolipoprotein B (apoB) is the most accurate marker of atherosclerotic cardiovascular disease (ASCVD) risk, its adoption in clinical practice has been low. This investigation sought to determine whether low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and triglycerides are sufficient for routine cardiovascular care. METHODS: A sample of 293 876 UK Biobank adults (age: 40-73 years, 42% men), free of cardiovascular disease, with a median follow-up for new-onset ASCVD of 11 years was included. Distribution of apoB at pre-specified levels of LDL-C, non-HDL-C, and triglycerides was examined graphically, and 10-year ASCVD event rates were compared for high vs. low apoB. Residuals of apoB were constructed after regressing apoB on LDL-C, non-HDL-C, and log-transformed triglycerides and used as predictors in a proportional hazards regression model for new-onset ASCVD adjusted for standard risk factors, including HDL-C. RESULTS: ApoB was highly correlated with LDL-C and non-HDL-C (Pearson's r = .96, P < .001 for both) but less so with log triglycerides (r = .42, P < .001). However, apoB ranges necessary to capture 95% of all observations at pre-specified levels of LDL-C, non-HDL-C, or triglycerides were wide, spanning 85.8-108.8 md/dL when LDL-C 130 mg/dL, 88.3-112.4 mg/dL when non-HDL-C 160 mg/dL, and 67.8-147.4 md/dL when triglycerides 115 mg/dL. At these levels (±10 mg/dL), 10-year ASCVD rates for apoB above mean + 1 SD vs. below mean - 1 SD were 7.3 vs. 4.0 for LDL-C, 6.4 vs. 4.6 for non-HDL-C, and 7.0 vs. 4.6 for triglycerides (all P < .001). With 19 982 new-onset ASCVD events on follow-up, in the adjusted model, residual apoB remained statistically significant after accounting for LDL-C and HDL-C (hazard ratio 1.06, 95% confidence interval 1.0-1.07), after accounting for non-HDL-C and HDL-C (hazard ratio 1.04, 95% confidence interval 1.03-1.06), and after accounting for triglycerides and HDL-C (hazard ratio 1.13, 95% confidence interval 1.12-1.15). None of the residuals of LDL-C, non-HDL-C, or of log triglycerides remained significant when apoB was included in the model. CONCLUSIONS: High variability of apoB at individual levels of LDL-C, non-HDL-C, and triglycerides coupled with meaningful differences in 10-year ASCVD rates and significant residual information contained in apoB for prediction of new-onset ASCVD events demonstrate that LDL-C, non-HDL-C, and triglycerides are not adequate proxies for apoB in clinical care.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sniderman AD, Dufresne L, Pencina KM, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024. PMID: 38700053. doi:10.1093/eurheartj/ehae258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。